BACKGROUND: The relationship between quantitative immunohistochemical hormone receptor expression and response to the combination of trastuzumab with chemotherapy in HER2-positive advanced breast cancer is currently unknown. METHODS: Estrogen receptor (ER) and progesterone receptor expression was studied both as a dichotomous variable (positivity set at ≥ 1% of positive cells) and as a continuous variable. The effect of hormone receptor expression on overall response rate and progression-free survival in patients receiving trastuzumab-based treatment was studied by univariate and multivariate analysis. RESULTS: One hundred eleven of 227 consecutive advanced breast cancer patients treated at 2 Institutions had hormone receptor-positive tumors (49%). High expression of ER (≥ 30% of tumor cells) predicted reduced probability of tumor response to trastuzumab plus chemotherapy (multivariate odds ratio, 0.422; 95% confidence interval [CI], 0.222-0.803; P = .009). In patients with hormone receptor-positive tumors (≥ 1% of tumor cells), maintenance endocrine therapy added to trastuzumab upon the completion of chemotherapy was associated with a significant progression-free survival benefit (hazard ratio, 0.521; 95% CI, 0.3325-0.836; P = .007). CONCLUSIONS: Our results suggest a predictive role of hormone receptor expression in HER2-positive tumors. Further investigation in this patient subset is warranted to optimize the use of HER2-targeting agents, chemotherapy, and endocrine therapy.
BACKGROUND: The relationship between quantitative immunohistochemical hormone receptor expression and response to the combination of trastuzumab with chemotherapy in HER2-positive advanced breast cancer is currently unknown. METHODS:Estrogen receptor (ER) and progesterone receptor expression was studied both as a dichotomous variable (positivity set at ≥ 1% of positive cells) and as a continuous variable. The effect of hormone receptor expression on overall response rate and progression-free survival in patients receiving trastuzumab-based treatment was studied by univariate and multivariate analysis. RESULTS: One hundred eleven of 227 consecutive advanced breast cancerpatients treated at 2 Institutions had hormone receptor-positive tumors (49%). High expression of ER (≥ 30% of tumor cells) predicted reduced probability of tumor response to trastuzumab plus chemotherapy (multivariate odds ratio, 0.422; 95% confidence interval [CI], 0.222-0.803; P = .009). In patients with hormone receptor-positive tumors (≥ 1% of tumor cells), maintenance endocrine therapy added to trastuzumab upon the completion of chemotherapy was associated with a significant progression-free survival benefit (hazard ratio, 0.521; 95% CI, 0.3325-0.836; P = .007). CONCLUSIONS: Our results suggest a predictive role of hormone receptor expression in HER2-positive tumors. Further investigation in this patient subset is warranted to optimize the use of HER2-targeting agents, chemotherapy, and endocrine therapy.
Authors: Debu Tripathy; Peter A Kaufman; Adam M Brufsky; Musa Mayer; Marianne Ulcickas Yood; Bongin Yoo; Cheng Quah; Denise Yardley; Hope S Rugo Journal: Oncologist Date: 2013-05-07
Authors: Michelle M Kim; Shaheenah Dawood; Pamela Allen; Aysegul A Sahin; Wendy A Woodward; Benjamin D Smith; Eric A Strom; Kelly K Hunt; Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo; Thomas A Buchholz Journal: Cancer Date: 2012-04-17 Impact factor: 6.860
Authors: Basma M Sharaf; Alexander D Giddey; Hamza M Al-Hroub; Varsha Menon; Javan Okendo; Raafat El-Awady; Muath Mousa; Ahmed Almehdi; Mohammad H Semreen; Nelson C Soares Journal: Cancer Chemother Pharmacol Date: 2022-10-20 Impact factor: 3.288
Authors: Iveta Kolarova; Ladislav Dusek; Ales Ryska; Karek Odrazka; Martin Dolezel; Jaroslav Vanasek; Bohuslav Melichar; Jiri Petera; Tomas Buchler; Milan Vosmik; Katarina Petrakova; Petra Terarova; Zdena Vilasova; Jiri Jarkovsky Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155